Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology
NCT ID: NCT05461599
Last Updated: 2023-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
2 participants
INTERVENTIONAL
2022-08-25
2023-05-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management
NCT05351866
A Mobile and Virtual Reality Intervention for Adolescent Depression
NCT04165681
Self-guided Treatment for Adolescents Navigating Depression
NCT05462652
A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19
NCT04524598
Targeting Adolescent Depressive Symptoms Via Brief, Web-Based Interventions
NCT04066985
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study aims involve evaluating:
* Feasibility of recruiting and enrolling adolescents with elevated symptoms of depression from the Cardiology and Gastroenterology programs at CHLA.
* Retention, program adherence, completion, and withdrawal rates.
* Safety of the intervention, including reported adverse and serious adverse events
* Perceived utility, usability, and enjoyment of the SparkRx app by adolescents
* Clinically significant changes in pre- to -post treatment depressive symptoms and persistence of such gains at 1 month follow up.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SparkRx Mobile App
The 5-week SparkRx app is divided into 5 levels intended to be completed weekly. A character called 'Limbot' is used as a guide. Limbot encourages the user in completing the behavioral activation program and provides personal examples of how they have undertaken behavioral activation therapy. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and Participant Symptom Check (PSC) questionnaire in the mobile app. Tasks in the mobile app progress in a linear fashion-- i.e., each task must be completed to progress to the next task. Certain on-demand resources can be accessed in the app at any time, including crisis resources. Text entries that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support.
SparkRx Mobile App
The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SparkRx Mobile App
The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate-severe self-reported symptoms of depression at baseline (PHQ-8 \>=5)
* Under the care of a US-based healthcare provider and willing and able to provide the name and contact information of the provider during consent
* English fluency or proficiency and literacy of adolescent and consenting legal guardian, if required
* Access to an eligible mobile device (capable of installing the app) and regular internet access
* Willing to provide informed e-consent/assent and have legal guardian willing to provide informed e consent (if required)
Exclusion Criteria
* Suicide attempt within the past year
* Active suicide ideation with intent
* Previously participated in user testing or clinical testing of the Spark app
* Any condition, comorbidity, or event that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefitting from the treatment (e.g., unable to perform informed assent or consent, treatment resistance as determined by investigator) or will prevent investigators from being able to ensure safety (e.g., will be leaving the country during study time period)
13 Years
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Hospital Los Angeles
OTHER
Limbix Health, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aarthi Padmanabhan, PhD
Role: PRINCIPAL_INVESTIGATOR
Limbix Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Limbix Health Inc.
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LMX-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.